三个皮匠报告
最新
报告分类 研搜
BETA
政策库
自研报告
new
入驻
搜索
您的当前位置：首页 > 行业数据 > PD(L)1*VEGF双抗针对一线CRC全球III期临床情况
图片属性
图片格式：PNG 图片大小：122KB 图片尺寸：2302*387
同报告图片
 / 4
PD(L)1*VEGF双抗针对一线CRC全球III期临床情况_第1页
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
PD(L)1*VEGF双抗针对一线CRC全球III期临床情况_第2页
PD(L)1*VEGF双抗针对一线CRC全球III期临床情况_第3页
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
PD(L)1*VEGF双抗针对一线CRC全球III期临床情况_第4页
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
PD(L)1*VEGF双抗针对一线CRC全球III期临床情况_第5页
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
所属报告： 荣昌生物（688331）-A股公司研究报告：2026年展望：加入全球肿瘤一线竞争-260312（17页）.pdf
打包全文图表

相关数据

最新数据
全行业研究报告分享下载平台
  • 0731-84720580
  • 商务合作：really158d
  • 友链申请 (QQ)：1737380874
关于我们
更多
关于我们
三个皮匠报告微信公众号
三个皮匠报告微信小程序
扫码咨询商务合作事宜
友情链接：
营销自动化 亿欧智库 微播易 阿里妈妈
copyright@2008-2013 长沙思想领动信息技术有限公司版权所有        网站备案/许可证号：湘B2-20190120 | 工信部备案号：湘ICP备2023027541号-2 | 公安备案号：湘公网安备43010402001071号
客服
商务合作
小程序
服务号
折叠